New Targeted Therapies Reshaping Kidney Disease Treatment

A surge of targeted therapies is beginning to reshape the treatment landscape for kidney disease, moving the field away from broad interventions toward drugs that intervene directly in the molecular pathways that cause organ damage.

For decades, options for the estimated 850 million people globally living with kidney disease were limited. Many of the most common treatments were not originally developed to treat the kidneys. This included blood-pressure medications such as angiotensin receptor blockers and ACE inhibitors, as well as SGLT2 inhibitors, which were initially created to treat type 2 diabetes.

A Shift Toward Molecular Targeting

Researchers are now shifting their focus toward the specific molecular drivers of kidney disease. This transition is supported by an increasing confidence among regulators in the use of surrogate endpoints, such as proteinuria—the presence of protein in the urine—to predict long-term patient outcomes.

This evolution in clinical approach is allowing for the development of a more robust pipeline of medications. According to Swapnil Hiremath, a nephrologist at the Ottawa Hospital in Canada, the influx of new options has been significant.

It’s been fantastic. We are getting new molecules all the time,

Swapnil Hiremath

FDA Approvals in 2025

The year 2025 saw several FDA approvals for medications designed to target specific causes of kidney damage, offering new ways to protect kidney function and slow the progression of various diseases.

One notable approval was Ozempic (semaglutide). Originally approved in 2017 for type 2 diabetes, the GLP-1 receptor agonist was approved in 2025 to protect the kidneys in adults who have both chronic kidney disease and type 2 diabetes. GLP-1s mimic a natural hormone to help control blood sugar and reduce stress on the heart and kidneys, which may lower the risk of kidney failure and heart-related death.

Other 2025 approvals focused on specific glomerular diseases and autoimmune conditions:

• Voyxact (sibeprenlimab-szsi): A monoclonal antibody approved for adults with IgA Nephropathy (IgAN). We see self-administered via injection every four weeks to target a protein in the immune system that contributes to kidney damage.
• Vanrafia: Also approved for the treatment of IgA Nephropathy.
• Fabhalta and Empaveli: Approved for Complement 3 Glomerulopathy (C3G), with Empaveli also indicated for IC-MPGN.
• Gazyva: Approved for the treatment of Lupus Nephritis.

Emerging Therapeutic Strategies

Beyond the recent approvals, researchers are pursuing diverse strategies to halt the progression toward end-stage renal disease. These include the development of genetically targeted therapies and drugs designed to block the complement cascade, a component of the immune system that can cause kidney damage when it becomes overactive.

These developments signal a broader transformation in nephrology, as the field moves from managing systemic symptoms like blood pressure to addressing the underlying biological mechanisms of kidney failure.